Skip to main content
Livermore
Livermore
ZHEN

Citadel Advisors LLC

SEC CIK
0001423053
Latest filing
Sep 1, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by Citadel Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
289,090
Value
$22.6M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of HALO by Citadel Advisors LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026289,090$22.6M<0.1%+98,039+51.3%AddedHolders
Q1 2026191,051$12.3M<0.1%+191,051NewHolders
Q4 20250$00.0%−244,801−100.0%Sold outHolders
Q3 2025244,801$18.0M<0.1%−66,597−21.4%ReducedHolders
Q2 2025311,398$16.2M<0.1%+231,991+292.2%AddedHolders
Q1 202579,407$5.07M<0.1%−1,183,350−93.7%ReducedHolders
Q4 20241,262,757$60.4M0.1%+1,262,757NewHolders
Q3 20240$00.0%−347,699−100.0%Sold outHolders
Q2 2024347,699$18.2M<0.1%+46,333+15.4%AddedHolders
Q1 2024301,366$12.3M<0.1%+116,602+63.1%AddedHolders
Q4 2023184,764$6.83M<0.1%+254+0.1%AddedHolders
Q3 2023184,510$7.05M<0.1%−967,309−84.0%ReducedHolders
Q2 20231,151,819$41.5M<0.1%+230,398+25.0%AddedHolders
Q1 2023921,421$35.2M<0.1%+669,147+265.2%AddedHolders
Q4 2022252,274$14.4M<0.1%+232,326+1,164.7%AddedHolders
Q3 202219,948$789.0K<0.1%−522,398−96.3%ReducedHolders
Q2 2022542,346$23.9M<0.1%+532,478+5,396.0%AddedHolders
Q1 20229,868$394.0K<0.1%−137,702−93.3%ReducedHolders
Q4 2021147,570$5.93M<0.1%+80,421+119.8%AddedHolders
Q3 202167,149$2.73M<0.1%−37,252−35.7%ReducedHolders
Q2 2021104,401$4.74M<0.1%−62,785−37.6%ReducedHolders
Q1 2021167,186$6.97M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.